Search Results
Matches for acronym pe
329
rows returned
Results are ranked by score and user rating. Use the quick vote buttons when a candidate clearly matches or clearly does not.
| Acronym | Full Name | Score | User Rating | Judge | Search |
|---|---|---|---|---|---|
| PE | pulmonary embolism | 398 | 3 | ||
| PE | phosphatidylethanolamine | 184 | 28 | ||
| PE | phenylephrine | 139 | 14 | ||
| PE | plasma exchange | 84 | 14 | ||
| PE | Pseudomonas exotoxin | 49 | 6 | ||
| PE | polyethylene | 26 | 9 | ||
| PE | Pseudomonas exotoxin A | 24 | 7 | ||
| PE | phycoerythrin | 22 | 1 | ||
| PE | plating efficiency | 18 | 28 | ||
| PE | phosphatidyl ethanolamine | 16 | 6 | ||
| PE | preeclampsia | 11 | 28 | ||
| PE | physical education | 11 | 26 | ||
| PE | pigment epithelium | 11 | 10 | ||
| PE | postexposure | 10 | 29 | ||
| PE | plasma exchanges | 10 | 27 | ||
| PE | physical examination | 10 | 6 | ||
| PE | Pericardial effusion | 9 | 27 | ||
| PE | pulmonary edema | 9 | 19 | ||
| PE | pigmented epithelial | 9 | 12 | ||
| PE | plasma extravasation | 8 | 11 | ||
| PE | pigmented epithelium | 8 | 10 | ||
| PE | pulmonary emphysema | 6 | 25 | ||
| PE | Pleural effusion | 6 | 5 | ||
| PE | Pleural effusion | 6 | 5 | ||
| PE | physical exercise | 5 | 29 | ||
| PE | persistent estrus | 5 | 11 | ||
| PE | pigmented ciliary epithelial | 5 | 10 | ||
| PE | proenkephalin | 5 | 10 | ||
| PE | phosphorylethanolamine | 5 | 9 | ||
| PE | parietal endoderm | 5 | 7 | ||
| PE | phosphatidylserine (PS) and phosphatidylethanolamine | 4 | 24 | ||
| PE | pleural effusions | 4 | 21 | ||
| PE | prolonged exposure in vivo | 4 | 14 | ||
| PE | plating efficiencies | 4 | 11 | ||
| PE | penile erection | 4 | 10 | ||
| PE | phosphatidylethanolamines | 4 | 3 | ||
| PE | Pregnenolone | 3 | 29 | ||
| PE | periventricular nucleus | 3 | 27 | ||
| PE | progressive encephalopathy | 3 | 27 | ||
| PE | pressure equalization | 3 | 12 | ||
| PE | pharyngoesophageal | 3 | 11 | ||
| PE | parasitized erythrocytes | 3 | 11 | ||
| PE | pre-eclampsia | 3 | 8 | ||
| PE | post-exposure | 3 | 7 | ||
| PE | promoter | 3 | 7 | ||
| PE | proliferative enteritis | 3 | 6 | ||
| PE | prolonged exposure | 3 | 6 | ||
| PE | falciparum-parasitized erythrocytes | 3 | 5 | ||
| PE | phosphoethanolamine | 3 | 4 | ||
| PE | phacoemulsification | 3 | 3 | ||
| PE | pulmonary thromboembolism | 2 | 37 | ||
| PE | preeclamptic | 2 | 27 | ||
| PE | physical exercises | 2 | 16 | ||
| PE | post exposure | 2 | 15 | ||
| PE | protective efficacy | 2 | 15 | ||
| PE | platelet extract | 2 | 15 | ||
| PE | performance error | 2 | 13 | ||
| PE | poor | 2 | 13 | ||
| PE | push enteroscopy | 2 | 12 | ||
| PE | pulmonary embolization | 2 | 12 | ||
| PE | protein extravasation | 2 | 12 | ||
| PE | phosphoglycerides | 2 | 11 | ||
| PE | beta-phenylethylamine | 2 | 10 | ||
| PE | polychromatic erythrocytes (MPE) among polychromatic erythrocytes | 2 | 10 | ||
| PE | perphenazine enanthate | 2 | 10 | ||
| PE | Polyelectrolyte | 2 | 10 | ||
| PE | pulmonary eosinophilia | 2 | 9 | ||
| PE | phenylephrine hydrochloride | 2 | 9 | ||
| PE | PEG-diisocyanate treated surfaces experienced 96% | 2 | 6 | ||
| PE | pearl | 2 | 6 | ||
| PE | pineal extract | 2 | 6 | ||
| PE | proximal element | 2 | 5 | ||
| PE | pars externa | 2 | 5 | ||
| PE | Polyurethane (PU) and polyethylene | 2 | 4 | ||
| PE | parasitized erythrocyte | 2 | 4 | ||
| PE | Precedence Effect | 2 | 4 | ||
| PE | psoriasis erythrodermica | 2 | 3 | ||
| PE | parallel elastic | 2 | 3 | ||
| PE | propylene oxide | 2 | 2 | ||
| PE | prolyl endopeptidase | 2 | 2 | ||
| PE | pseudoexfoliation syndrome | 2 | 1 | ||
| PE | cisplatin-etoposide | 2 | -1 | ||
| PE | previous experience comparing cisplatin/etoposide | 1 | 36 | ||
| PE | peritoneal effluent | 1 | 36 | ||
| PE | peripheral blood eosinophilia | 1 | 34 | ||
| PE | palpation examination | 1 | 33 | ||
| PE | polyethyleneglycol(PEG)-phosphatidylethanolamine | 1 | 31 | ||
| PE | Periapical exudates | 1 | 29 | ||
| PE | production of erythrocytes | 1 | 29 | ||
| PE | pregnancy-induced hypertension (PIH) and preeclampsia | 1 | 29 | ||
| PE | primary extranodal | 1 | 29 | ||
| PE | polychromatic erythroblasts | 1 | 29 | ||
| PE | (R)-phycoerythrin | 1 | 28 | ||
| PE | dioleoyl-phosphatidylcholine (PC) and dioleoyl-phosphatidylethanolamine | 1 | 28 | ||
| PE | pigeon erythrocytes | 1 | 28 | ||
| PE | pemphigus erythematosus | 1 | 27 | ||
| PE | point estimates | 1 | 27 | ||
| PE | paraffin embedded | 1 | 27 | ||
| PE | 5-amino-1-pentanol | 1 | 27 | ||
| PE | pleural empyema | 1 | 27 | ||
| PE | proliferative endometria | 1 | 26 | ||
| PE | prostate epithelial | 1 | 26 | ||
| PE | propofol on phenylephrine | 1 | 26 | ||
| PE | phenelzine (PLZ) or of beta-phenylethylamine | 1 | 26 | ||
| PE | phosphatidylcholine (PC) and ethanolamine | 1 | 25 | ||
| PE | phosphatidyl ethanolamines | 1 | 25 | ||
| PE | polyethyleneglycol (PEG)-phosphatidylethanolamine | 1 | 25 | ||
| PE | parabolic wave equation | 1 | 25 | ||
| PE | plaque enlargement | 1 | 25 | ||
| PE | cis-platin/etoposide | 1 | 24 | ||
| PE | polyethers | 1 | 23 | ||
| PE | pure ethanol | 1 | 23 | ||
| PE | platinum + epirubicin | 1 | 23 | ||
| PE | polarizable electropole | 1 | 22 | ||
| PE | persistent-estrous | 1 | 22 | ||
| PE | preceded by pectin methylesterase | 1 | 22 | ||
| PE | proestrus | 1 | 22 | ||
| PE | presence of phosphatidylethanolamine | 1 | 22 | ||
| PE | physician's extender | 1 | 20 | ||
| PE | Phthalate esters | 1 | 20 | ||
| PE | probe-earmold | 1 | 19 | ||
| PE | person equivalent | 1 | 19 | ||
| PE | penile enlargement | 1 | 18 | ||
| PE | patients with failed Kasai portoenterostomy | 1 | 18 | ||
| PE | phosphoglyceride fraction | 1 | 18 | ||
| PE | placentome to phenylephrine | 1 | 18 | ||
| PE | Proportionate expansion | 1 | 18 | ||
| PE | ORAC | 1 | 17 | ||
| PE | phase encoding | 1 | 16 | ||
| PE | primers in an automated 377 sequencer | 1 | 16 | ||
| PE | auristatin-phenethylamine | 1 | 16 | ||
| PE | patients with suspected pulmonary thromboembolism | 1 | 16 | ||
| PE | phenol | 1 | 15 | ||
| PE | Peclet number | 1 | 15 | ||
| PE | Proton enhanced | 1 | 15 | ||
| PE | probability of exclusion | 1 | 14 | ||
| PE | mildest--premature ejaculation | 1 | 14 | ||
| PE | phosphate contents | 1 | 14 | ||
| PE | percentage of platelets binding phycoerythrin | 1 | 14 | ||
| PE | Plasma-exchange | 1 | 14 | ||
| PE | PIH or preeclampsia | 1 | 14 | ||
| PE | PMN were labeled with phycoerythrin-E | 1 | 14 | ||
| PE | paraffin-embedded | 1 | 14 | ||
| PE | population equivalent | 1 | 14 | ||
| PE | paralytic esotropia | 1 | 14 | ||
| PE | phycobiliproteins phycoerythrin | 1 | 13 | ||
| PE | phase of the unsaturated dioleoylphosphatidylethanolamine | 1 | 13 | ||
| PE | plasmaexchange | 1 | 13 | ||
| PE | phosphate ester | 1 | 13 | ||
| PE | propidium iodide (PI) and R-phycoerythrin | 1 | 12 | ||
| PE | placental extract | 1 | 12 | ||
| PE | proportional error | 1 | 12 | ||
| PE | pleiotropic effects | 1 | 12 | ||
| PE | primarily ethanolamine | 1 | 12 | ||
| PE | patients and patients with pre-eclampsia | 1 | 12 | ||
| PE | 2-diacyl-sn-glycero-3-phosphoethanolamine | 1 | 12 | ||
| PE | polyethene | 1 | 12 | ||
| PE | projection encoding | 1 | 12 | ||
| PE | plasma norepinephrine (PNE) or epinephrine | 1 | 12 | ||
| PE | phosphatidylcholine (PC) phosphatidylethanolamine | 1 | 12 | ||
| PE | probe fluo-3 and using R-phycoerythrin | 1 | 12 | ||
| PE | Parodi endograft | 1 | 12 | ||
| PE | physician extenders | 1 | 12 | ||
| PE | proteinuria | 1 | 12 | ||
| PE | proteoglycan-degrading enzymes | 1 | 12 | ||
| PE | primary clarifier effluent | 1 | 11 | ||
| PE | propionyl esterase | 1 | 11 | ||
| PE | pressure | 1 | 11 | ||
| PE | preventive effect on pulmonary edema | 1 | 11 | ||
| PE | periventricular preoptic nucleus | 1 | 11 | ||
| PE | N-acyl-phosphatidylethanolamine | 1 | 11 | ||
| PE | partial pressure | 1 | 11 | ||
| PE | Peak enhancement | 1 | 11 | ||
| PE | anti-phosphatidylethanolamine | 1 | 11 | ||
| PE | permeability coefficients | 1 | 11 | ||
| PE | phospholipids phosphatidylcholine (PC) and phosphatidylethanolamine | 1 | 11 | ||
| PE | pertioneal exudate | 1 | 11 | ||
| PE | propylene gas | 1 | 11 | ||
| PE | peritonitis | 1 | 11 | ||
| PE | packed erythrocytes | 1 | 10 | ||
| PE | pars esophageal | 1 | 10 | ||
| PE | pore's radius | 1 | 10 | ||
| PE | program evaluation | 1 | 10 | ||
| PE | pathway was pregnenolone | 1 | 10 | ||
| PE | Péclet number | 1 | 10 | ||
| PE | properties of polyethylene | 1 | 10 | ||
| PE | primordial epithelium | 1 | 10 | ||
| PE | pectinesterase | 1 | 10 | ||
| PE | phosphatidy glycerols (PG) and phosphatidylethanolamine | 1 | 10 | ||
| PE | processed vinyl resins and polyethylene | 1 | 10 | ||
| PE | Pseudomonas aeruginosa elastase | 1 | 10 | ||
| PE | pure erythrocytosis | 1 | 10 | ||
| PE | pinealectomy | 1 | 10 | ||
| PE | plasma glucosylceramide (GlcCer) or phosphatidylethanolamine | 1 | 10 | ||
| PE | phosphatidyleth-anolamine | 1 | 9 | ||
| PE | PC and phosphatidylethanolamine | 1 | 9 | ||
| PE | prostaglandin E-1 | 1 | 9 | ||
| PE | pulmonary endocrine | 1 | 9 | ||
| PE | plasma estrone | 1 | 9 | ||
| PE | posthypoxic encephalopathies | 1 | 9 | ||
| PE | preliminary exercise | 1 | 9 | ||
| PE | pregnancy and preeclampsia | 1 | 9 | ||
| PE | pregnancies complicated by severe preeclampsia | 1 | 9 | ||
| PE | PERA/Ei | 1 | 9 | ||
| PE | preexposed | 1 | 9 | ||
| PE | phorbol ester | 1 | 9 | ||
| PE | early | 1 | 9 | ||
| PE | predominantly epithelioid | 1 | 9 | ||
| PE | pseudoexfoliation | 1 | 9 | ||
| PE | phospholipids phosphatidylethanolamine | 1 | 9 | ||
| PE | polyethylene terephthalate (PET) and polyethylene | 1 | 9 | ||
| PE | phospholipids labeled were phosphatidylethanolamine | 1 | 9 | ||
| PE | parasitized (Plasmodium berghei) erythrocytes | 1 | 9 | ||
| PE | Proopiomelanocortin (POMC) and proenkephalin | 1 | 9 | ||
| PE | passive extensibility | 1 | 9 | ||
| PE | partial (70%) hepatectomy on phosphatidylethanolamine | 1 | 9 | ||
| PE | exclamans | 1 | 9 | ||
| PE | R-phycoerythrin | 1 | 9 | ||
| PE | pasteurization effect | 1 | 9 | ||
| PE | phospholipid phosphatidylethanolamine | 1 | 9 | ||
| PE | primarily incorporated into phosphatidylethanolamine | 1 | 8 | ||
| PE | peritoneal cavity | 1 | 8 | ||
| PE | Positive expectancies | 1 | 8 | ||
| PE | periapical exudate | 1 | 8 | ||
| PE | physical exam | 1 | 8 | ||
| PE | Phosphorothioate (PS)-capped phosphodiester | 1 | 8 | ||
| PE | extravidin-R-phycoerythrin | 1 | 8 | ||
| PE | patients' archived paraffin-embedded | 1 | 8 | ||
| PE | pigmented ciliary epithelial cells | 1 | 8 | ||
| PE | polyhedron envelope | 1 | 8 | ||
| PE | pre eclamptic | 1 | 8 | ||
| PE | pulmonary | 1 | 8 | ||
| PE | pigmented ciliary epithelium | 1 | 8 | ||
| PE | pectin | 1 | 8 | ||
| PE | pituitary extract | 1 | 8 | ||
| PE | precisternal elements | 1 | 8 | ||
| PE | [14C]arachidonoylphosphatidylethanolamine | 1 | 7 | ||
| PE | PEG-filgrastim, | 1 | 7 | ||
| PE | Proportions of phosphatidylethanolamine | 1 | 7 | ||
| PE | pyroglutamic | 1 | 7 | ||
| PE | probability equivalence approach | 1 | 7 | ||
| PE | pulmonary embolisms | 1 | 7 | ||
| PE | patients with IBD using phycoerythrin | 1 | 7 | ||
| PE | PC to phosphatidylethanolamine | 1 | 7 | ||
| PE | priming exercise | 1 | 7 | ||
| PE | phenylethylamine | 1 | 7 | ||
| PE | Physical Evaluation | 1 | 7 | ||
| PE | preferentially hydrolyzes phosphatidylethanolamine | 1 | 7 | ||
| PE | phosphatidylcholine (PC)/phosphatidylethanolamine | 1 | 7 | ||
| PE | Phytoestrogens | 1 | 7 | ||
| PE | Platinum and Etoposide | 1 | 7 | ||
| PE | phosphatidylcholines (PC) or phosphatidylethanolamines | 1 | 7 | ||
| PE | plasma exudation | 1 | 7 | ||
| PE | positive by day 14 postexposure | 1 | 7 | ||
| PE | phospholipase D hydrolyses phosphatidylethanolamine | 1 | 6 | ||
| PE | possible pathogenetic factor of preeclampsia | 1 | 6 | ||
| PE | phospholipids were phosphatidylethanolamine | 1 | 6 | ||
| PE | phospholipids combined with phosphatidylethanolamine | 1 | 6 | ||
| PE | processing elements | 1 | 6 | ||
| PE | pre-mixed fluorescein isothiocyanate (FITC) and R-phycoerythrin | 1 | 6 | ||
| PE | peak-equivalent | 1 | 6 | ||
| PE | proportion of errors | 1 | 6 | ||
| PE | portal circulations | 1 | 6 | ||
| PE | posterior ectosylvian | 1 | 6 | ||
| PE | Prompt commencement of plasma-exchange | 1 | 6 | ||
| PE | phospholipid methylation which converts phosphatidylethanolmine | 1 | 6 | ||
| PE | phosphati-dylethanolamine | 1 | 6 | ||
| PE | phenylepherine | 1 | 6 | ||
| PE | persistent type-II endoleaks | 1 | 6 | ||
| PE | pulse energy | 1 | 6 | ||
| PE | d-pseudoephedrine | 1 | 6 | ||
| PE | yoelii-parasitized erythrocytes | 1 | 6 | ||
| PE | pulmonary eosinophiles | 1 | 6 | ||
| PE | product and pro-enkephalin | 1 | 6 | ||
| PE | perimeter | 1 | 6 | ||
| PE | pericardial effusions | 1 | 6 | ||
| PE | pulmonary edema (HAPE) from pulmonary embolism | 1 | 6 | ||
| PE | physical examination by trained personnel | 1 | 6 | ||
| PE | plasmalogens (EP) and phosphatidylethanolamine | 1 | 5 | ||
| PE | polyclonal antibody biotinylated ELISA | 1 | 5 | ||
| PE | placebo+exposure | 1 | 5 | ||
| PE | plasmid DNA vaccine | 1 | 5 | ||
| PE | prostaglandin E1 | 1 | 5 | ||
| PE | plus etoposide | 1 | 5 | ||
| PE | protected environment | 1 | 5 | ||
| PE | poorly on phosphatidylethanolamine | 1 | 5 | ||
| PE | Phosphatidylinositolmannosides and phosphatidylethanolamine | 1 | 5 | ||
| PE | prior exercise | 1 | 5 | ||
| PE | prediction error | 1 | 5 | ||
| PE | phophatidylethanolamine | 1 | 5 | ||
| PE | peritumoral edema | 1 | 5 | ||
| PE | pregnancy edema | 1 | 5 | ||
| PE | poly(ethylene) | 1 | 4 | ||
| PE | promotes the methylation of phosphatidylethanolamine | 1 | 4 | ||
| PE | Penne | 1 | 4 | ||
| PE | peptide E | 1 | 4 | ||
| PE | dioleoylphosphatidylethanolamine | 1 | 4 | ||
| PE | diacyl-phosphatidylethanolamine | 1 | 4 | ||
| PE | prematurity effect | 1 | 4 | ||
| PE | Portoenterostomy | 1 | 4 | ||
| PE | anti-CD-14-phycoerythrin | 1 | 4 | ||
| PE | PH are pulmonary thromboemboli | 1 | 4 | ||
| PE | primer extension | 1 | 4 | ||
| PE | Gd-DTPA-phosphatidylethanolamine | 1 | 4 | ||
| PE | Pseudomonas elastase | 1 | 4 | ||
| PE | potassium (K+) or phenylephrine | 1 | 4 | ||
| PE | 1-palmitoyl-2-stearoyl glycerophosphoethanolamine | 1 | 3 | ||
| PE | postembolization | 1 | 3 | ||
| PE | phospholipids including phosphatidylethanolamine | 1 | 3 | ||
| PE | proliferative effect | 1 | 3 | ||
| PE | polyethylene terephthalate (PET) or polyester | 1 | 3 | ||
| PE | Epinephrine | 1 | 2 | ||
| PE | potato extracts | 1 | 2 | ||
| PE | primary treatment effluent water | 1 | 2 | ||
| PE | prominent ears | 1 | 2 | ||
| PE | pectus excavatum | 1 | 2 | ||
| PE | probability of sire exclusion | 1 | 2 | ||
| PE | provided they contained phosphatidylethanolamine | 1 | 2 | ||
| PE | pancreatic enzymes | 1 | 2 | ||
| PE | phosphorous esters | 1 | 2 | ||
| PE | proteolytic enzymes | 1 | 2 | ||
| PE | pallium externum | 1 | 2 | ||
| PE | pre-exposed | 1 | 2 | ||
| PE | phenylephrine HC1 | 1 | 1 | ||
| PE | principally with phosphatidylethanolamine | 1 | 1 | ||
| PE | pyroglutamate | 1 | 1 | ||
| PE | phosphatidylethanolamino | 1 | 0 | ||
| PE | primitive endoderm | 1 | -1 | ||
| PE | phycocyanin (PC) and phycoerythrin | 1 | -2 |
Run A Search
Search either direction
By Acronym
By Full Name